Hemophagocytic syndromes - An update

Blood Reviews

Volumn 28, Issue 4, 2014, Pages 135-142

  Janka, Gritta E ^a   Lehmberg, Kai ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Adult HLH; Hemophagocytic lymphohistiocytosis; Immune deficiency; Macrophage activation syndrome; Reduced intensity conditioning; Stem cell transplantation

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; CYCLOSPORIN A; CYTOKINE ANTIBODY; CYTOSTATIC AGENT; DEXAMETHASONE; ETOPOSIDE; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; T LYMPHOCYTE ANTIBODY; THYMOCYTE ANTIBODY;

AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; CENTRAL NERVOUS SYSTEM; CYTOKINE STORM; CYTOTOXIC T LYMPHOCYTE; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DOWN REGULATION; EPSTEIN BARR VIRUS INFECTION; FUNCTION TEST; GENETIC DISORDER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HEPATOSPLENOMEGALY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFECTION; MACROPHAGE ACTIVATION SYNDROME; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; NONHUMAN; PANCYTOPENIA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEPSIS; SYMPTOM; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VISCERAL LEISHMANIASIS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC;

HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC;

EID: 84903132528     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.03.002     Document Type: Article

References (108)

1. Janka G.E. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 2007, 166:95-109.
2. Henter J.I., Carlson L.A., Soder O., Nilsson-Ehle P., Elinder G. Lipoprotein alterations and plasma lipoprotein lipase reduction in familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand 1991, 80:675-681.
3. Loscalzo J. The macrophage and fibrinolysis. Semin Thromb Hemost 1996, 22:503-506.
4. Recalcati S., Invernizzi P., Arosio P., Cairo G. New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. J Autoimmun 2008, 30:84-89.
5. Wu J.R., Yuan L.X., Ma Z.G., Chen X.X., Gu L., Gao J. GDF15-mediated upregulation of ferroportin plays a key role in the development of hyperferritinemia in children with hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2013, 60:940-945.
6. Kuriyama T., Takenaka K., Kohno K., Yamauchi T., Daitoku S., Yoshimoto G., et al. Engulfment of hematopoietic stem cells caused by down-regulation of CD47 is critical in the pathogenesis of hemophagocytic lymphohistiocytosis. Blood 2012, 120:4058-4067.
7. Rohr J., Beutel K., Maul-Pavicic A., Vraetz T., Thiel J., Warnatz K., et al. Atypical familial hemophagocytic lymphohistiocytosis due to mutations in UNC13D and STXBP2 overlaps with primary immunodeficiency diseases. Haematologica 2010, 95:2080-2087.
8. Sandrock K., Nakamura L., Vraetz T., Beutel K., Ehl S., Zieger B. Platelet secretion defect in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL-5). Blood 2010, 116:6148-6150.
9. Ren Q., Wimmer C., Chicka M.C., Ye S., Ren Y., Hughson F.M., et al. Munc13-4 is a limiting factor in the pathway required for platelet granule release and hemostasis. Blood 2010, 116:869-877.
10. Monfregola J., Johnson J.L., Meijler M.M., Napolitano G., Catz S.D. MUNC13-4 protein regulates the oxidative response and is essential for phagosomal maturation and bacterial killing in neutrophils. J Biol Chem 2010, 287:44603-44618.
11. Zhao X.W., Gazendam R.P., Drewniak A., van Houdt M., Tool A.T., van Hamme J.L., et al. Defects in neutrophil granule mobilization and bactericidal activity in familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) syndrome caused by STXBP2/Munc18-2 mutations. Blood 2013, 122:109-111.
12. Speckmann C., Lehmberg K., Albert M.H., Damgaard R.B., Fritsch M., Gyrd-Hansen M., et al. X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis. Clin Immunol 2013, 149:133-141.
13. Ishii E., Ohga S., Imashuku S., Yasukawa M., Tsuda H., Miura I., et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 2007, 86:58-65.
14. Kawaguchi H., Miyashita T., Herbst H., Niedobitek G., Asada M., Tsuchida M., et al. Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome. J Clin Invest 1993, 92:1444-1450.
15. Beutel K., Gross-Wieltsch U., Wiesel T., Stadt U.Z., Janka G., Wagner H.J. Infection of T lymphocytes in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin. Pediatr Blood Cancer 2009, 53:184-190.
16. Hong M., Ko Y.H., Yoo K.H., Koo H.H., Kim S.J., Kim W.S., et al. EBV-Positive T/NK-Cell Lymphoproliferative Disease of Childhood. Korean J Pathol 2013, 47:137-147.
17. Schaer D.J., Schaer C.A., Schoedon G., Imhof A., Kurrer M.O. Hemophagocytic macrophages constitute a major compartment of heme oxygenase expression in sepsis. Eur J Haematol 2006, 77:432-436.
18. Vincent J.L., Opal S.M., Marshall J.C., Tracey K.J. Sepsis definitions: time for change. Lancet 2013, 381:774-775.
19. Giannoudis P.V. Current concepts of the inflammatory response after major trauma: an update. Injury 2003, 34:397-404.
20. Atteritano M., David A., Bagnato G., Beninati C., Frisina A., Iaria C., et al. Haemophagocytic syndrome in rheumatic patients A systematic review. Eur Rev Med Pharmacol Sci 2012, 16:1414-1424.
21. Behrens E.M., Canna S.W., Slade K., Rao S., Kreiger P.A., Paessler M., et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest 2011, 121:2264-2277.
22. Ravelli A., Grom A.A., Behrens E.M., Cron R.Q. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012, 13:289-298.
23. Lehmberg K., Ehl S. Diagnostic evaluation of patients with suspected haemophagocytic lymphohistiocytosis. Br J Haematol 2013, 160:275-287.
24. Booth C., Gilmour K.C., Veys P., Gennery A.R., Slatter M.A., Chapel H., et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood 2011, 117:53-62.
25. Emmenegger U., Reimers A., Frey U., Fux C., Bihl F., Semela D., et al. Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation. Swiss Med Wkly 2002, 132:230-236.
26. Fardet L., Lambotte O., Meynard J.L., Kamouh W., Galicier L., Marzac C., et al. Reactive haemophagocytic syndrome in 58 HIV-1-infected patients: clinical features, underlying diseases and prognosis. Aids 2010, 24:1299-1306.
27. Karras A., Thervet E., Legendre C. Hemophagocytic syndrome in renal transplant recipients: report of 17 cases and review of literature. Transplantation 2004, 77:238-243.
28. Abe Y., Choi I., Hara K., Matsushima T., Nishimura J., Inaba S., et al. Hemophagocytic syndrome: a rare complication of allogeneic nonmyeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant 2002, 29:799-801.
29. Zhang K., Jordan M.B., Marsh R.A., Johnson J.A., Kissell D., Meller J., et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood 2011, 118:5794-5798.
30. Duval M., Fenneteau O., Doireau V., Faye A., Emilie D., Yotnda P., et al. Intermittent hemophagocytic lymphohistiocytosis is a regular feature of lysinuric protein intolerance. J Pediatr 1999, 134:236-239.
31. Kardas F., Patiroglu T., Unal E., Chiang S.C., Bryceson Y.T., Kendirci M. Hemophagocytic syndrome in a 4-month-old infant with biotinidase deficiency. Pediatr Blood Cancer 2013, 59:191-193.
32. Wu S., Gonzalez-Gomez I., Coates T., Yano S. Cobalamin C disease presenting with hemophagocytic lymphohistiocytosis. Pediatr Hematol Oncol 2005, 22:717-721.
33. Gokce M., Unal O., Hismi B., Gumruk F., Coskun T., Balta G., et al. Secondary hemophagocytosis in 3 patients with organic acidemia involving propionate metabolism. Pediatr Hematol Oncol 2012, 29:92-98.
34. Karaman S., Urganci N., Günsel K., Cetinkaya F. Niemann - Pick disease associated with hemophagocytic syndrome. Turk J Haematol 2010, 27:303-307.
35. Kundak A.A., Zenciroglu A., Yarali N., Saygili Karagol B., Dursun A., Gokce S., et al. An unusual presentation of galactosemia: hemophagocytic lymphohistiocytosis. Turk J Haematol 2012, 29:401-404.
36. Topaloglu R., Lebre A.S., Demirkaya E., Kuskonmaz B., Coskun T., Orhan D., et al. Two new cases with Pearson syndrome and review of Hacettepe experience. Turk J Pediatr 2008, 50:572-576.
37. Venkatasubramani N., Verbsky J., Rudolph C., Sood M. Hemophagocytic lymphohistiocytosis with multiorgan involvement in children with chronic intestinal pseudo-obstruction receiving parenteral nutrition support. J Pediatr Gastroenterol Nutr 2012, 55:218-220.
38. Pastore S., Barbieri F., Leo G.D., Valencic E., Tommasini A., Ventura A. Hemophagocytic Lymphohistiocytosis in Total Parenteral Nutrition Dependent Children: Description of 5 Cases and Practical Tips for Management. J Pediatr Hematol Oncol Jul 3 2013, [epub ahead of print].
39. Aronson I.K., Worobec S.M. Cytophagic histiocytic panniculitis and hemophagocytic lymphohistiocytosis: an overview. Dermatol Ther 2010, 23:389-402.
40. Barrett D.M., Teachey D.T., Grupp S.A. Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr 2014, 26:43-49.
41. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
42. Krebs P., Crozat K., Popkin D., Oldstone M.B., Beutler B. Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice. Blood 2011, 117:6582-6588.
43. Fall N., Barnes M., Thornton S., Luyrink L., Olson J., Ilowite N.T., et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum 2007, 56:3793-3804.
44. Tristano A.G. Macrophage activation syndrome: a frequent but under-diagnosed complication associated with rheumatic diseases. Med Sci Monit 2008, 14:RA27-RA36.
45. Martinon F. Signaling by ROS drives inflammasome activation. Eur J Immunol 2010, 40:616-619.
46. de Saint Basile G., Menasche G., Fischer A. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol 2010, 10:568-579.
47. Jessen B., Kogl T., Sepulveda F.E., de Saint Basile G., Aichele P., Ehl S. Graded defects in cytotoxicity determine severity of hemophagocytic lymphohistiocytosis in humans and mice. Front Immunol 2013, 4:448.
48. Kogl T., Muller J., Jessen B., Schmitt-Graeff A., Janka G., Ehl S., et al. Hemophagocytic lymphohistiocytosis in syntaxin-11-deficient mice: T-cell exhaustion limits fatal disease. Blood 2013, 121:604-613.
49. Chen M., Felix K., Wang J. Critical role for perforin and Fas-dependent killing of dendritic cells in the control of inflammation. Blood 2012, 119:127-136.
50. Waggoner S.N., Cornberg M., Selin L.K., Welsh R.M. Natural killer cells act as rheostats modulating antiviral T cells. Nature 2012, 481:394-398.
51. Kagi D., Odermatt B., Mak T.W. Homeostatic regulation of CD8+ T cells by perforin. Eur J Immunol 1999, 29:3262-3272.
52. Lykens J.E., Terrell C.E., Zoller E.E., Risma K., Jordan M.B. Perforin is a critical physiologic regulator of T-cell activation. Blood 2012, 118:618-626.
53. Terrell C.E., Jordan M.B. Mixed hematopoietic or T-cell chimerism above a minimal threshold restores perforin-dependent immune regulation in perforin-deficient mice. Blood 2013, 122:2618-2621.
54. Huang J.F., Yang Y., Sepulveda H., Shi W., Hwang I., Peterson P.A., et al. TCR-Mediated internalization of peptide-MHC complexes acquired by T cells. Science 1999, 286:952-954.
55. Verbsky J.W., Grossman W.J. Hemophagocytic lymphohistiocytosis: diagnosis, pathophysiology, treatment, and future perspectives. Ann Med 2006, 38:20-31.
56. Sinha S., Mishra S.K., Sharma S., Patibandla P.K., Mallick P.K., Sharma S.K., et al. Polymorphisms of TNF-enhancer and gene for FcgammaRIIa correlate with the severity of falciparum malaria in the ethnically diverse Indian population. Malar J 2008, 7:13.
57. Poggi A., Costa P., Tomasello E., Moretta L. IL-12-induced up-regulation of NKRP1A expression in human NK cells and consequent NKRP1A-mediated down-regulation of NK cell activation. Eur J Immunol 1998, 28:1611-1616.
58. Jerome K.R., Tait J.F., Koelle D.M., Corey L. Herpes simplex virus type 1 renders infected cells resistant to cytotoxic T-lymphocyte-induced apoptosis. J Virol 1998, 72:436-441.
59. Xu A., Bellamy A.R., Taylor J.A. Immobilization of the early secretory pathway by a virus glycoprotein that binds to microtubules. Embo J 2000, 19:6465-6474.
60. Trottestam H., Berglof E., Horne A., Onelov E., Beutel K., Lehmberg K., et al. Risk factors for early death in children with haemophagocytic lymphohistiocytosis. Acta Paediatr 2011, 101:313-318.
61. Wada T., Muraoka M., Yokoyama T., Toma T., Kanegane H., Yachie A. Cytokine profiles in children with primary Epstein-Barr virus infection. Pediatr Blood Cancer 2013, 60:E46-E48.
62. Horne A., Trottestam H., Arico M., Egeler R.M., Filipovich A.H., Gadner H., et al. Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. Br J Haematol 2008, 140:327-335.
63. Yang S., Zhang L., Jia C., Ma H., Henter J.I., Shen K. Frequency and development of CNS involvement in Chinese children with hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2010, 54:408-415.
64. Deiva K., Mahlaoui N., Beaudonnet F., de Saint Basile G., Caridade G., Moshous D., et al. CNS involvement at the onset of primary hemophagocytic lymphohistiocytosis. Neurology 2012, 78:1150-1156.
65. Rego I., Severino M., Micalizzi C., Faraci M., Pende D., Dufour C., et al. Neuroradiologic findings and follow-up with magnetic resonance imaging of the genetic forms of haemophagocytic lymphohistiocytosis with CNS involvement. Pediatr Blood Cancer 2011, 58:810-814.
66. Gurgey A., Aytac S., Balta G., Oguz K.K., Gumruk F. Central nervous system involvement in Turkish children with primary hemophagocytic lymphohistiocytosis. J Child Neurol 2008, 23:1293-1299.
67. Lehmberg K., Pink I., Eulenburg C., Beutel K., Maul-Pavicic A., Janka G. Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis. J Pediatr 2013, 162:1245-1251.
68. Pagel J., Beutel K., Lehmberg K., Koch F., Maul-Pavicic A., Rohlfs A.K., et al. Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5). Blood 2012, 119:6016-6024.
69. Balta G., Azik F.M., Gurgey A. Defective UNC13D Gene-associated Familial Hemophagocytic Lymphohistiocytosis Triggered by Visceral Leishmaniasis: A Diagnostic Challenge. J Pediatr Hematol Oncol 2014, 36:e42-e45.
70. Hazen M.M., Woodward A.L., Hofmann I., Degar B.A., Grom A., Filipovich A.H., et al. Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum 2008, 58:567-570.
71. Bryceson Y.T., Pende D., Maul-Pavicic A., Gilmour K.C., Ufheil H., Vraetz T., et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 2012, 119:2754-2763.
72. Marsh R.A., Bleesing J.J., Filipovich A.H. Using flow cytometry to screen patients for X-linked lymphoproliferative disease due to SAP deficiency and XIAP deficiency. J Immunol Methods 2010, 362:1-9.
73. Meeths M., Chiang S.C., Wood S.M., Entesarian M., Schlums H., Bang B., et al. Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D. Blood 2011, 118:5783-5793.
74. Trottestam H., Horne A., Arico M., Egeler R.M., Filipovich A.H., Gadner H., et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood 2011, 118:4577-4584.
75. Mahlaoui N., Ouachee-Chardin M., de Saint Basile G., Neven B., Picard C., Blanche S., et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics 2007, 120:e622-e628.
76. Chen R.L., Lin K.H., Lin D.T., Su I.J., Huang L.M., Lee P.I., et al. Immunomodulation treatment for childhood virus-associated haemophagocytic lymphohistiocytosis. Br J Haematol 1995, 89:282-290.
77. Johnson T.S., Terrell C.E., Millen S.H., Katz J.D., Hildeman D.A., Jordan M.B. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol 2013, 192:84-91.
78. Jackson J., Titman P., Butler S., Bond K., Rao A., Veys P., et al. Cognitive and psychosocial function post hematopoietic stem cell transplantation in children with hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol 2013, 132:889-895. [e881-883].
79. Marsh R.A., Allen C.E., McClain K.L., Weinstein J.L., Kanter J., Skiles J., et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 2013, 60:101-109.
80. Ladisch S., Ho W., Matheson D., Pilkington R., Hartman G. Immunologic and clinical effects of repeated blood exchange in familial erythrophagocytic lymphohistiocytosis. Blood 1982, 60:814-821.
81. Demirkol D., Yildizdas D., Bayrakci B., Karapinar B., Kendirli T., Koroglu T.F., et al. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?. Crit Care 2012, 16:R52.
82. Olin R.L., Nichols K.E., Naghashpour M., Wasik M., Shelly B., Stadtmauer E.A., et al. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am J Hematol 2008, 83:747-749.
83. Pachlopnik Schmid J., Ho C.H., Chretien F., Lefebvre J.M., Pivert G., Kosco-Vilbois M., et al. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med 2009, 1:112-124.
84. Chellapandian D., Das R., Zelley K., Wiener S.J., Zhao H., Teachey D.T., et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol 2013, 162:376-382.
85. Cascio A., Pernice L.M., Barberi G., Delfino D., Biondo C., Beninati C., et al. Secondary hemophagocytic lymphohistiocytosis in zoonoses A systematic review. Eur Rev Med Pharmacol Sci 2012, 16:1324-1337.
86. Castillo L., Carcillo J. Secondary hemophagocytic lymphohistiocytosis and severe sepsis/ systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med 2009, 10:387-392.
87. Baker K.S., Filipovich A.H., Gross T.G., Grossman W.J., Hale G.A., Hayashi R.J., et al. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant 2008, 42:175-180.
88. Ohga S., Kudo K., Ishii E., Honjo S., Morimoto A., Osugi Y., et al. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Pediatr Blood Cancer 2010, 54:299-306.
89. Ouachee-Chardin M., Elie C., de Saint Basile G., Le Deist F., Mahlaoui N., Picard C., et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics 2006, 117:e743-e750.
90. Marsh R.A., Jordan M.B., Filipovich A.H. Reduced-intensity conditioning haematopoietic cell transplantation for haemophagocytic lymphohistiocytosis: an important step forward. Br J Haematol 2011, 154:556-563.
91. Cooper N., Rao K., Goulden N., Webb D., Amrolia P., Veys P. The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis. Bone Marrow Transplant 2008, 42(Suppl. 2):S47-S50.
92. Lehmberg K., Albert M.H., Beier R., Beutel K., Gruhn B., Kroger N., et al. Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis. Haematologica 2014, 99:180-184.
93. Marsh R.A., Kim M.O., Liu C., Bellman D., Hart L., Grimley M., et al. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Biol Blood Marrow Transplant 2013, 19:1625-1631.
94. Horne A., Janka G., Maarten Egeler R., Gadner H., Imashuku S., Ladisch S., et al. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol 2005, 129:622-630.
95. Sawada A., Ohga S., Ishii E., Inoue M., Okada K., Inagaki J., et al. Feasibility of reduced-intensity conditioning followed by unrelated cord blood transplantation for primary hemophagocytic lymphohistiocytosis: a nationwide retrospective analysis in Japan. Int J Hematol 2013, 98:223-230.
96. Marsh R.A., Rao K., Satwani P., Lehmberg K., Muller I., Li D., et al. Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood 2012, 121:877-883.
97. Henter J.I., Horne A., Arico M., Egeler R.M., Filipovich A.H., Imashuku S., et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007, 48:124-131.
98. Sieni E., Cetica V., Santoro A., Beutel K., Mastrodicasa E., Meeths M., et al. Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3. J Med Genet 2011, 48:343-352.
99. Zur Stadt U., Beutel K., Kolberg S., Schneppenheim R., Kabisch H., Janka G., et al. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. Hum Mutat 2006, 27:62-68.
100. Macartney C.A., Weitzman S., Wood S.M., Bansal D., Steele M., Meeths M., et al. Unusual functional manifestations of a novel STX11 frameshift mutation in two infants with familial hemophagocytic lymphohistiocytosis type 4 (FHL4). Pediatr Blood Cancer 2011, 56:654-657.
101. Enders A., Zieger B., Schwarz K., Yoshimi A., Speckmann C., Knoepfle E.M., et al. Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood 2006, 108:81-87.
102. Huck K., Feyen O., Niehues T., Ruschendorf F., Hubner N., Laws H.J., et al. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest 2009, 119:1350-1358.
103. Seidel M.G. CD27: a new player in the field of common variable immunodeficiency and EBV-associated lymphoproliferative disorder?. J Allergy Clin Immunol 2012, 129:1175. [author reply 1175-1176].
104. Perry R., Kecha O., Paquette J., Huot C., Van Vliet G., Deal C. Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital Montreal. J Clin Endocrinol Metab 2005, 90:3243-3250.
105. Stark Z., Savarirayan R. Osteopetrosis. Orphanet J Rare Dis 2009, 4:5.
106. Rudman Spergel A., Walkovich K., Price S., Niemela J.E., Wright D., Fleisher T.A., et al. Autoimmune lymphoproliferative syndrome misdiagnosed as hemophagocytic lymphohistiocytosis. Pediatrics 2013, 132:e1440-e1444.
107. Whitington P.F. Neonatal hemochromatosis: a congenital alloimmune hepatitis. Semin Liver Dis 2007, 27:243-250.
108. Sharpe L.R., Ancliff P., Amrolia P., Gilmour K.C., Vellodi A. Type II Gaucher disease manifesting as haemophagocytic lymphohistiocytosis. J Inherit Metab Dis 2009, 32(Suppl. 1):S107-S110.